High Flow Nasal Cannula and Mask Oxygenation in Patients With Visceral Obesity Undergoing Sedated Gastroscopy
1 other identifier
interventional
200
1 country
1
Brief Summary
During sedated gastroscopy, the insertion of the fiberscope and gastric distension required to perform the examination may induce respiratory depression, airway obstruction, and decreased chest wall compliance. Patients with obesity, especially visceral fat, have poor lung and chest wall compliance, lower lung capacity and functional residual capacity, and an unbalanced ventilation-to-perfusion ratio. Thus, obese patients are at a high risk of hypoxemia. Increasing evidence supports the use of High-flow nasal cannula (HFNC) oxygenation in obese patients during sedated gastrointestinal endoscopy. Obesity, especially visceral obesity, is an established risk factor associated with all-cause mortality. Body roundness index (BRI) is a newer anthropometric measure associated with identification of high-risk individuals. Owing to the limited evidence, we designed this unblinded randomized controlled trial to assess whether HFNC, compared to standard mask oxygenation, improves oxygenation at the end of the procedure (primary endpoint) in patients with visceral obesity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2025
CompletedStudy Start
First participant enrolled
August 31, 2025
CompletedFirst Posted
Study publicly available on registry
September 8, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2026
December 1, 2025
November 1, 2025
10 months
August 27, 2025
November 27, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of hypoxia
SpO2\<90%
From sedation with propofol to the end of the gastroscopy
Secondary Outcomes (4)
Incidence of subclinical respiratory depression
From sedation with propofol to the end of the gastroscopy
Severe hypoxia
From sedation with propofol to the end of the gastroscopy
Serious cardiac events
Through gastroscopy completion, an average of 10-15 minutes
Serious adverse respiratory events
Through gastroscopy completion, an average of 10-15 minutes
Study Arms (2)
High Flow Nasal Cannula Oxygenation
EXPERIMENTALHigh Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
Mask Oxygenation
ACTIVE COMPARATORConventional Oxygenation will be administered through mask
Interventions
High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
conventional oxygen therapy will be administered through common mask with a flow up to 6 Liters per minute
Eligibility Criteria
You may qualify if:
- ASA class ≤Ⅲ
- Visceral obesity(body mass index≥28 and BRI ≥5.46)
- Patients who will undergo sedated gastroscopy
You may not qualify if:
- Life-threatening heart disease or acute myocardial infarction within 6 weeks
- Presence of pneumothorax or pulmonary bullae, pulmonary embolism, pulmonary oedema
- Upper respiratory tract infection
- Presence of tracheostomy
- Nasal or nasopharyngeal diseases
- Coagulation disorders or a tendency of nose bleeding
- Pregnancy
- Recent (within 1 week) thoracic surgery
- Emergent procedure or surgery
- Allergy to drugs used during the procedure
- Unwillingness to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongshan Hospitla
Shanghai, China
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 27, 2025
First Posted
September 8, 2025
Study Start
August 31, 2025
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
July 31, 2026
Last Updated
December 1, 2025
Record last verified: 2025-11